Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): a multicentre, double-blind, randomised, placebo-controlled, phase 3b study. - Giovannoni G; Airas L; Bove R; Cutter GR; Czarnecki M; Drulovic J; Hobart J; Kuhle J; Montalban X; Selmaj KW; Tur C; Wolinsky JS; et al. (Lancet (London, England), 2026)